15 Result(s)
-
Article
Open AccessThree-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection?
To analyze the 3-month life expectancy rate in pancreatic cancer (PC) patients treated within prospective trials from the German AIO study group.
-
Article
Open AccessA Retrospective Analysis of Biliary Tract Cancer Patients Presented to the Molecular Tumor Board at the Comprehensive Cancer Center Munich
With the rising importance of precision oncology in biliary tract cancer (BTC), the aim of this retrospective single-center analysis was to describe the clinical and molecular characteristics of patients with ...
-
Article
Open AccessSerum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IFN-γ, TNF-α and PD-1/PD-L1 in comparison to established serum tumor markers
Novel biomarkers to better predict outcome and select the best therapeutic strategy for the individual patient are necessary for pancreatic ductal adenocarcinoma (PDAC).
-
Article
Open AccessPrecision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunichLMU Molecular Tumor Board
In pancreatic cancer, systemic treatment options in addition to chemotherapy remain scarce, and so far only a small proportion of patients benefit from targeted therapies.
-
Article
Prolonged time to treatment initiation in advanced pancreatic cancer patients has no major effect on treatment outcome: a retrospective cohort study controlled for lead time bias and waiting time paradox
A prolonged time to treatment initiation (TTI) correlates with an adverse prognosis in different cancer types including resectable pancreatic cancer (PC). Only limited evidence on the correlation between TTI a...
-
Article
POLE gene hotspot mutations in advanced pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease, lacking relevant prognostic and predictive biomarkers. DNA polymerase epsilon (POLE) has important functions in the maintenance of genetic stabili...
-
Article
Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer
Activating KRAS mutations are reported in up to 90% of pancreatic cancers. Refametinib potently inhibits MEK1/2, part of the MAPK signaling pathway. This phase I/II study evaluated the safety and efficacy of refa...
-
Article
Acinar cell carcinoma of the pancreas: a rare disease with different diagnostic and therapeutic implications than ductal adenocarcinoma
Acinar cell carcinoma (ACC) of the pancreas is a very rare cancer, constituting 1 % of all malignant non-endocrine pancreatic tumors. Only very limited data exist to guide treatment in patients with advanced ACC.
-
Article
Vier Jahre spezialisierte ambulante Palliativversorgung (SAPV) im ländlichen Bereich
Im Jahr 2011 wurde in den Landkreisen Landshut und Dingolfing erstmals eine spezialisierte ambulante Palliativversorgung (SAPV) eingeführt.
-
Article
ALK expression is absent in pancreatic ductal adenocarcinoma
It has not yet been clearly defined whether anaplastic lymphoma kinase (ALK) expression can be detected in pancreatic ductal adenocarcinoma (PDAC).
-
Article
KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer
It has not yet been defined if KRAS has a prognostic value or is a predictive biomarker for the efficacy of erlotinib in advanced pancreatic cancer (PC).
-
Article
Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy
CA 19-9 is the only established tumor marker in pancreatic cancer (PC); the prognostic role of other serum markers like CEA, CRP, LDH or bilirubin has not yet been defined.
-
Chapter
Diagnostik und Therapie beim Rezidiv des Pankreaskarzinoms
Auch nach einer Resektion in kurativer Absicht ist das duktale Adenokarzinom des Pankreas mit einer hohen Rezidivrate verbunden. Für eine strukturierte Nachsorge zur frühzeitigen Erkennung eines Rezidivs gibt ...
-
Chapter and Conference Paper
Eliminating Complex Treatment Setup for Intact Breast or Postmastectomy Treatment with Intensity Modulated Radiation Therapy
Intensity Modulation Radiation Therapy (IMRT) for intact breast or chest wall treatments has been controversial based on the results of recent studies. One study indicates that IMRT significantly reduces norma...
-
Article
Laminin-5 bei Erkrankungen der Mundhöhle
